KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $4.4 billion.

  • Gilead Sciences' Operating Expenses fell 3327.32% to $4.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 billion, marking a year-over-year decrease of 3231.55%. This contributed to the annual value of $27.1 billion for FY2024, which is 3885.5% up from last year.
  • Latest data reveals that Gilead Sciences reported Operating Expenses of $4.4 billion as of Q3 2025, which was down 3327.32% from $4.6 billion recorded in Q2 2025.
  • Gilead Sciences' 5-year Operating Expenses high stood at $11.0 billion for Q1 2024, and its period low was $3.5 billion during Q1 2021.
  • Over the past 5 years, Gilead Sciences' median Operating Expenses value was $4.6 billion (recorded in 2025), while the average stood at $5.1 billion.
  • In the last 5 years, Gilead Sciences' Operating Expenses surged by 13688.4% in 2024 and then plummeted by 5975.65% in 2025.
  • Over the past 5 years, Gilead Sciences' Operating Expenses (Quarter) stood at $6.3 billion in 2021, then dropped by 18.75% to $5.1 billion in 2022, then increased by 7.42% to $5.5 billion in 2023, then decreased by 7.0% to $5.1 billion in 2024, then decreased by 13.19% to $4.4 billion in 2025.
  • Its Operating Expenses stands at $4.4 billion for Q3 2025, versus $4.6 billion for Q2 2025 and $4.4 billion for Q1 2025.